Ischemic Cardiomyopathy
Introduction
Section titled “Introduction”Background
Section titled “Background”Ischemic cardiomyopathy (ICM) is a serious form of heart muscle disease characterized by impaired cardiac function resulting from a persistent reduction in blood flow (ischemia) to the myocardium. This condition is most commonly a consequence of severe coronary artery disease (CAD), where the coronary arteries—responsible for supplying oxygenated blood to the heart—become narrowed or blocked, leading to chronic oxygen deprivation of the heart muscle.[1]Over time, this sustained lack of adequate blood supply can lead to significant damage and remodeling of the heart, making ICM a leading cause of heart failure globally.
Biological Basis
Section titled “Biological Basis”The biological foundation of ischemic cardiomyopathy involves a complex interplay of chronic myocardial ischemia, cellular injury, and maladaptive remodeling of the heart. Prolonged oxygen deprivation can cause myocardial stunning (temporary loss of function), hibernation (reduced function to conserve energy), and ultimately, the death of heart muscle cells (cardiomyocytes), replaced by fibrotic tissue. This process weakens the heart’s pumping ability. While atherosclerosis and CAD are the primary drivers, an individual’s genetic makeup significantly influences susceptibility to CAD and the progression of ICM. Genetic research, including large-scale genome-wide association studies (GWAS), has identified numerous single nucleotide polymorphisms (SNPs) associated with various cardiac structural and functional traits, such as left ventricular (LV) mass and overall heart function, which are crucial in the context of ICM.[2] For instance, SNPs located near genes like ALPK3, BAG3, CLCNKA/HSPB7, FHOD3, and FLNC have been linked to cardiac magnetic resonance (CMR) imaging phenotypes, offering insights into the genetic architecture underlying diverse cardiomyopathies, including those with an ischemic origin.[1]Furthermore, studies indicate shared genetic susceptibility between ischemic stroke and coronary artery disease, underscoring the broader genetic predisposition to ischemic conditions.[3]
Clinical Relevance
Section titled “Clinical Relevance”Clinically, ischemic cardiomyopathy often manifests with symptoms characteristic of heart failure, such as shortness of breath, profound fatigue, and peripheral edema. Accurate diagnosis and assessment of ICM typically involve advanced imaging modalities like cardiac magnetic resonance (CMR) imaging, which provides detailed information on ventricular function, myocardial viability, and the extent of scarring or fibrotic tissue.[2]Genetic insights into ICM are increasingly relevant for risk stratification, identifying individuals predisposed to developing the condition, and potentially guiding more personalized therapeutic strategies. Research also explores the impact of various physiological traits, such as systolic blood pressure and glycemic traits, onLV structure and function, highlighting their roles in the pathogenesis of ICM.[4]
Social Importance
Section titled “Social Importance”Ischemic cardiomyopathy poses a substantial public health challenge worldwide due to its high prevalence, significant morbidity, and considerable mortality rates. It severely diminishes patients’ quality of life and places an immense economic burden on healthcare systems. Understanding the genetic contributions to ICM is paramount for developing more effective preventive strategies, improving diagnostic accuracy, and identifying novel targets for therapeutic interventions. By elucidating the complex genetic landscape of ICM, genomic research aims to facilitate precision medicine approaches, ultimately striving to mitigate the global impact of this debilitating heart condition.
Methodological and Statistical Considerations
Section titled “Methodological and Statistical Considerations”Many studies face limitations in statistical power due to relatively small sample sizes, which increases the likelihood of false-negative findings for genetic associations of smaller magnitude or rare single nucleotide polymorphisms (SNPs).[5] This reduced power can hinder the detection of modest genetic effects, necessitating larger cohorts or meta-analyses for robust discovery.[6] Furthermore, the validation of identified markers for clinical risk prediction requires independent replication in additional, diverse cohorts, as initial findings may not always be consistently replicated across different studies.[7] The extensive multiple testing inherent in genome-wide association studies (GWAS) can increase the harvest of false positives, even when validation strategies are employed to mitigate this risk.[5] Additionally, heterogeneity in study design and phenotypic definitions across various investigations can diminish statistical power, particularly in meta-analyses, making it challenging to identify subtle genetic effects consistently.[6] Some analyses also did not perform explicit multiplicity adjustment, which could potentially inflate the significance of observed associations.[8]
Phenotypic Definition and Accuracy
Section titled “Phenotypic Definition and Accuracy”A significant limitation arises from the reliance on diagnostic codes to identify study outcomes, which inherently carries a risk of misclassification for cases.[7]Such misclassification is expected to dilute the strength of observed associations, potentially obscuring true genetic links to ischemic cardiomyopathy. Furthermore, the application of uniform thresholds for defining normal left ventricular size and function, without considering sex-specific differences, may lead to the inclusion of individuals whose measurements fall just outside the normal range when sex-adjusted criteria are applied.[7] The accuracy of phenotypic measurements is crucial, and errors in echocardiographic assessments can bias estimates towards the null, impeding the detection of genuine genetic associations.[6] For instance, M-mode echocardiography, while common, may provide less accurate measurements for certain structures like the aortic root, potentially leading to underestimation compared to two-dimensional imaging.[6] These methodological nuances in phenotyping can collectively contribute to remaining knowledge gaps regarding the precise genetic underpinnings of cardiac structure and function.
Generalizability and Gene-Environment Interactions
Section titled “Generalizability and Gene-Environment Interactions”A notable limitation in many genetic studies is the inclusion of cohorts predominantly composed of individuals of similar European ancestry, often to mitigate issues related to population substructure.[7]While this approach helps control for spurious associations, it significantly curtails the generalizability of findings to other ancestral groups, potentially overlooking population-specific genetic variants or effect sizes that contribute to ischemic cardiomyopathy risk in diverse populations. This narrow representation limits the comprehensive understanding of genetic contributions across the global population.
The interplay between genetic variants and environmental factors is a critical, yet often underexplored, aspect of complex traits like ischemic cardiomyopathy.[9] Genetic variants can exert their influence in a context-specific manner, with environmental modifiers such as dietary intake, like salt, significantly altering associations between genes (e.g., ACE and AGTR2) and cardiac phenotypes.[9]The absence of comprehensive investigations into these gene-environment interactions represents a substantial knowledge gap, contributing to the phenomenon of missing heritability and an incomplete picture of disease etiology.
Variants
Section titled “Variants”The genetic variants rs112941217 in the LMNA gene, rs112844193 in KIF26B, and rs3779381 in WNT16are of interest for their potential roles in cardiovascular health, including susceptibility to ischemic cardiomyopathy. These single nucleotide polymorphisms (SNPs) can influence critical cellular processes that maintain cardiac function and respond to stress. Understanding their impact helps elucidate the complex genetic architecture underlying heart disease, where numerous genetic factors contribute to overall risk and disease progression.[2]Extensive research has focused on identifying such genetic markers associated with various cardiac traits and conditions, including left ventricular mass, a key indicator of cardiac health.[6] The LMNA gene encodes lamins A and C, which are essential components of the nuclear lamina, a protein meshwork providing structural support to the cell nucleus. Beyond its structural role, LMNA is involved in chromatin organization, gene regulation, and DNA repair. Mutations in LMNAare well-established causes of a group of disorders known as laminopathies, which frequently manifest as dilated cardiomyopathy, often accompanied by conduction system disease and arrhythmias. The variantrs112941217 could potentially alter LMNAgene expression or protein function, thereby affecting nuclear integrity and cellular mechanotransduction within cardiomyocytes. Such alterations might weaken the heart muscle’s ability to withstand stress, making it more vulnerable to damage from ischemia and contributing to the development or progression of ischemic cardiomyopathy.[6] Genetic variations influencing cardiac structure and function are broadly studied to understand their contribution to heart conditions.[2] The KIF26B gene belongs to the kinesin family, which are motor proteins crucial for intracellular transport, cell division, and maintaining cytoskeletal structure. In cardiac cells, proper intracellular transport and cytoskeletal dynamics are vital for maintaining cardiomyocyte shape, contractility, and efficient signaling. Disruptions in kinesin function can lead to impaired cellular organization and function. The variant rs112844193 within KIF26Bmight influence the efficiency of cellular transport or the stability of the cytoskeleton, potentially affecting how cardiomyocytes respond to metabolic stress or injury. In the context of ischemic cardiomyopathy, compromised cellular integrity or impaired transport of essential molecules could exacerbate cellular damage during periods of reduced blood flow, hindering repair mechanisms and promoting maladaptive cardiac remodeling.[10]These genetic factors can contribute to the overall predisposition to cardiovascular diseases, including those leading to ischemic cardiomyopathy.[11] The WNT16gene is a member of the Wingless-related integration site (Wnt) signaling pathway, which plays a fundamental role in embryonic development, cell proliferation, differentiation, and tissue homeostasis, including bone development and immune responses. In the cardiovascular system, Wnt signaling is implicated in cardiac development, angiogenesis, and the fibrotic response to injury. The variantrs3779381 could modulate WNT16expression or activity, thereby influencing Wnt pathway signaling. Dysregulation of Wnt signaling in the heart can lead to altered cardiomyocyte survival, excessive fibrosis, or impaired regenerative capacity following ischemic events. Such effects can contribute to maladaptive cardiac remodeling, leading to progressive heart failure typical of ischemic cardiomyopathy. Therefore, variants likers3779381 may affect the heart’s ability to repair itself after ischemic injury, influencing long-term outcomes.[2]The genetic landscape of cardiac conditions is increasingly recognized for its impact on disease susceptibility and progression.[6]
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs112941217 | LMNA | ischemic cardiomyopathy |
| rs112844193 | KIF26B | ischemic cardiomyopathy |
| rs3779381 | WNT16 | spine bone mineral density femoral neck bone mineral density bone quantitative ultrasound heel bone mineral density ischemic cardiomyopathy |
Defining Ischemic Cardiomyopathy and its Etiological Basis
Section titled “Defining Ischemic Cardiomyopathy and its Etiological Basis”Ischemic cardiomyopathy is a specific form of heart muscle disease characterized by impaired cardiac function, primarily left ventricular (LV) systolic dysfunction, which directly results from myocardial ischemia caused by underlying coronary artery disease (CAD). This condition represents a significant clinical manifestation where chronic or recurrent reduction in blood flow to the heart muscle leads to structural remodeling and functional decline of the ventricles. The conceptual framework for ischemic cardiomyopathy firmly establishes coronary artery disease, involving the narrowing or blockage of the coronary arteries, as the fundamental etiological factor driving the myocardial damage.
The terminology “ischemic cardiomyopathy” is precise in denoting the ischemic origin of the heart muscle dysfunction, thereby distinguishing it from other cardiomyopathies that stem from non-ischemic causes. Coronary artery disease (CAD) is a critically related concept, often discussed alongside ischemic cardiomyopathy due to its direct role in the disease’s pathogenesis. Understanding CAD as the root pathological process involving arterial obstruction and subsequent myocardial ischemia is essential for comprehending the nature and classification of ischemic cardiomyopathy.
Diagnostic Parameters and Echocardiographic Assessment
Section titled “Diagnostic Parameters and Echocardiographic Assessment”The definitive diagnosis of ischemic cardiomyopathy relies on concurrently identifying significant coronary artery disease and establishing the presence of left ventricular systolic dysfunction. Left ventricular systolic dysfunction is operationally defined by specific quantitative criteria: a reduced fractional shortening of less than 0.29, which corresponds to an ejection fraction of 50% when assessed by M-mode echocardiography, or a diminished ejection fraction below 50% as determined by 2-dimensional echocardiography.[12] These thresholds serve as critical cut-off values for identifying the characteristic impairment in the heart’s pumping ability.
Echocardiography is a primary non-invasive modality used for comprehensive assessment of cardiac structure and function, providing key measurements for both diagnosis and ongoing monitoring. Specific parameters such as left ventricular internal dimension, the thicknesses of the posterior wall and interventricular septum, and the diameter of the aortic root are measured at end-diastole, while the left atrium diameter is obtained at end-systole.[12]These measurements are acquired using a leading edge technique and are averaged over three cardiac cycles, adhering to established American Society of Echocardiography guidelines, enabling the calculation of derived metrics like left ventricular wall thickness and left ventricular mass.[12]Additionally, cardiac magnetic resonance (CMR) imaging contributes to a detailed assessment with parameters such as indexed left ventricular mass, maximum and minimum left atrial volume indexed, left atrial emptying fraction, and right ventricular ejection fraction.[8]
Classification and Associated Clinical Context
Section titled “Classification and Associated Clinical Context”Ischemic cardiomyopathy is broadly classified as a secondary form of dilated cardiomyopathy, specifically differentiated by its origin in coronary artery disease. While the researchs does not explicitly delineate distinct subtypes of ischemic cardiomyopathy, its severity is implicitly graded by the extent of the underlying coronary artery disease and the measured degree of left ventricular dysfunction, notably through parameters such as the ejection fraction.[12]This categorical approach to classification emphasizes its etiology, positioning it within the nosological system of cardiovascular diseases as a condition distinct from other cardiomyopathies of non-ischemic origin.
Several clinical conditions and risk factors are strongly associated with the development and progression of ischemic cardiomyopathy, primarily by predisposing individuals to coronary artery disease. These include diabetes, hypertension, and hyperlipidemia, which are identified as significant risk factors based on either meeting established diagnostic criteria or receiving treatment for these conditions.[13]Obesity, quantified by a body-mass index (BMI) — calculated as weight in kilograms divided by the square of height in meters — also represents a substantial modifiable risk factor.[13]Furthermore, a reported parental or validated sibling history of coronary artery disease highlights the role of genetic and familial predispositions in the overall clinical context of ischemic cardiomyopathy.[13]
Clinical Presentation and Symptom Spectrum
Section titled “Clinical Presentation and Symptom Spectrum”Ischemic cardiomyopathy often manifests through a spectrum of clinical presentations, primarily related to impaired cardiac function and reduced pumping efficiency. Common symptoms include dyspnea, fatigue, and reduced exercise tolerance, which are characteristic of heart failure. The disease can present as left ventricular (LV) systolic dysfunction, defined by a diminished ejection fraction (EF) typically below 50% when measured by 2-dimensional echocardiography or M-mode, or as LV diastolic dysfunction, encompassing asymptomatic forms with preserved ejection fraction (DDpEF) or overt heart failure with preserved ejection fraction (HFpEF).[12]The severity of presentation can vary significantly, ranging from subtle, asymptomatic structural changes to severe, symptomatic heart failure requiring substantial medical intervention.
Beyond typical heart failure symptoms, individuals may present with signs indicative of cardiac remodeling. These include an increased left ventricular mass or altered left ventricular internal dimensions, which can be detected through imaging.[12]In older populations, an enlarged aortic root dimension can serve as a prognostic indicator, predicting future adverse cardiovascular events such as heart failure, stroke, and increased cardiovascular or all-cause mortality.[14]Such objective structural changes, even in the absence of overt symptoms, underscore the progressive nature of the disease and its potential for severe outcomes.
Advanced Imaging and Objective Assessment
Section titled “Advanced Imaging and Objective Assessment”The diagnosis and comprehensive evaluation of ischemic cardiomyopathy heavily rely on advanced imaging modalities that provide objective measures of cardiac structure and function. Cardiovascular Magnetic Resonance (CMR) imaging is a pivotal tool, enabling the derivation of quantitative phenotypes like left ventricular mass, left ventricular end-diastolic volume, and ejection fraction with high precision.[2]Deep learning-enabled analysis of CMR images further refines these assessments, allowing for the identification of subtle morphological changes, such as cardiac sphericity, which has been identified as an early marker of cardiomyopathy and related outcomes.[15]Echocardiography remains a fundamental diagnostic tool, offering insights into cardiac chamber quantification, LV mass, LV diastolic internal dimension, LV wall thickness, aortic root size, and left atrial size.[12]Specialized echocardiographic techniques, such as speckle-tracking echocardiography, and feature-tracking cardiac magnetic resonance imaging, allow for the quantification of global longitudinal strain and global circumferential strain. These strain measurements correlate with left ventricular ejection fraction and invasive diastolic functional indices, proving valuable in characterizing patients with heart failure with preserved ejection fraction.[16] Additionally, genetic analyses, including genome-wide association studies (GWAS) and whole-exome sequencing, contribute to diagnosis by identifying genetic variants associated with cardiac structure and function, such as those near ALPK3, BAG3, CLCNKA/HSPB7, FHOD3, and FLNC, and specific genes like MYRIP, TRAPPC11, and SLC27A6linked to left ventricular hypertrophy.[1]
Phenotypic Variability and Prognostic Significance
Section titled “Phenotypic Variability and Prognostic Significance”The clinical presentation and progression of ischemic cardiomyopathy are marked by significant phenotypic heterogeneity, influenced by various factors including individual genetic makeup, age, and ancestry. Studies have highlighted inter-individual variability, with specific genetic variants contributing to differences in cardiac structure and function, and the penetrance of monogenic variants can be modified by an individual’s polygenic background, leading to diverse clinical outcomes.[17]For instance, research in African Ancestry Populations has identified unique genetic associations with left ventricular hypertrophy, underscoring the importance of population-specific genetic insights.[14] Furthermore, electrocardiographic traits like the PR interval and QRS duration, indicative of cardiac conduction, also show genetic influence and variability.[18]Certain signs and measurements carry significant diagnostic and prognostic value, acting as red flags for disease progression and outcomes. Prognostically important left ventricular imaging phenotypes, such as those derived from CMR, are highly heritable and provide crucial information for risk stratification.[19]Left ventricular hypertrophy is a known independent predictor of cardiovascular mortality, highlighting its diagnostic significance.[14]The early detection capabilities of techniques like speckle tracking echocardiography, which can identify uremic cardiomyopathy and predict cardiovascular mortality in patients with end-stage renal disease, demonstrate the clinical correlation between objective measures and patient prognosis.[20] These tools allow for early intervention and personalized management strategies to mitigate adverse events.
Causes
Section titled “Causes”Ischemic cardiomyopathy arises from a complex interplay of genetic predispositions, environmental factors, and various comorbidities that collectively compromise myocardial blood supply and function. This condition primarily results from chronic ischemic injury to the heart muscle, often stemming from coronary artery disease, leading to structural and functional changes in the left ventricle. Understanding its causes requires examining contributions from inherent biological factors and external influences.
Genetic Predisposition and Cardiac Structure
Section titled “Genetic Predisposition and Cardiac Structure”Genetic factors play a significant role in an individual’s susceptibility to ischemic cardiomyopathy by influencing underlying cardiovascular traits and predisposing to coronary artery disease (CAD). Both Mendelian forms, involving single gene mutations, and polygenic risk, where multiple genetic variants contribute small effects, are implicated. For instance, specific mutations in sarcomeric protein genes, such as the cardiac myosin binding protein-C gene (MYBPC3), have been linked to familial cardiomyopathies like hypertrophic cardiomyopathy, which can alter cardiac structure and function, potentially increasing vulnerability to ischemic damage.[21], [22] Beyond monogenic forms, a polygenic background can modify the penetrance of these monogenic variants, highlighting complex gene-gene interactions.[17]Genome-wide association studies (GWAS) have identified numerous genetic variants associated with cardiac structure and function, including those influencing left ventricular mass, electrocardiographic traits like the PR interval, and systemic factors like blood pressure, all of which contribute to cardiovascular risk.[2], [18], [23], [24]Furthermore, common genetic variation in regions like the 3′-BCL11B gene desert has been associated with increased arterial stiffness and a higher risk of cardiovascular disease, contributing to the development of ischemic conditions.[25]Genetic susceptibility to coronary artery disease itself is well-established, with multiple loci identified that increase the likelihood of atherosclerotic plaque formation, the primary driver of myocardial ischemia.[13], [26]
Environmental and Lifestyle Influences
Section titled “Environmental and Lifestyle Influences”Environmental and lifestyle factors are critical determinants in the development and progression of ischemic cardiomyopathy, often by exacerbating genetic predispositions or directly inducing cardiovascular damage. Poor diet, lack of physical activity, and other lifestyle choices contribute significantly to the development of metabolic risk factors such as hypertension and dyslipidemia. For example, Mendelian randomization studies have demonstrated a causal effect of elevated systolic blood pressure on adverse left ventricular structure and function, a key precursor to ischemic cardiomyopathy.[4]Similarly, unfavorable glycemic traits, often influenced by diet and lifestyle, have been shown to impact left ventricular structure and function.[27]Environmental exposures, including socioeconomic factors and geographic influences, can also contribute to disparities in lifestyle choices and access to healthcare, indirectly impacting the prevalence of cardiovascular risk factors. Additionally, specific lifestyle elements like sleep duration have been found to interact with genetic loci to influence lipid profiles, indicating that sleep habits can modulate metabolic pathways relevant to cardiovascular health.[28]
Interplay of Genetics and Environment in Disease Pathogenesis
Section titled “Interplay of Genetics and Environment in Disease Pathogenesis”The development of ischemic cardiomyopathy is not solely dictated by either genetics or environment but rather by their intricate interactions. Genetic predispositions can render individuals more vulnerable to environmental triggers, while protective environmental factors can mitigate genetic risks. A notable example is the observed interaction between genetic variants (SNPs) and lifestyle factors such as sleep duration, which collectively influence lipid levels—a crucial component of cardiovascular risk.[28]This highlights how an individual’s genetic makeup can modulate their physiological response to environmental stimuli. The polygenic background, representing the cumulative effect of many genetic variants, can significantly modify the penetrance and expression of both monogenic variants and environmentally induced conditions, thereby shaping an individual’s overall risk for developing ischemic heart disease and subsequent cardiomyopathy.[17]These gene-environment interactions underscore the personalized nature of disease risk and the potential for lifestyle interventions to be particularly impactful in genetically susceptible individuals.
Comorbidities and Age-Related Cardiac Remodeling
Section titled “Comorbidities and Age-Related Cardiac Remodeling”Several comorbidities and the natural process of aging significantly contribute to the onset and progression of ischemic cardiomyopathy. Chronic conditions such as hypertension and diabetes are well-established risk factors for cardiovascular disease, leading to structural and functional alterations in the heart. High systolic blood pressure, a common comorbidity, directly impacts left ventricular structure and function, increasing the workload on the heart and promoting adverse remodeling.[4] Similarly, dysregulated glycemic traits, characteristic of diabetes, can independently influence left ventricular mechanics and contribute to myocardial damage.[27]Beyond specific diseases, the aging process itself plays a crucial role, with age-related changes in vascular and cardiac anatomy contributing to increased risk. For example, age-related changes in aortic arch geometry are strongly linked to proximal aortic function and affect left ventricular mass and remodeling, influencing the heart’s ability to pump blood effectively and potentially exacerbating ischemic conditions.[29]These cumulative effects of comorbidities and age-related physiological changes create a fertile ground for the development of chronic myocardial ischemia and subsequent cardiomyopathy.
Biological Background
Section titled “Biological Background”Ischemic cardiomyopathy is a complex cardiac condition characterized by reduced blood flow to the heart muscle, typically due to coronary artery disease, leading to impaired heart function and structural changes. This chronic state of myocardial ischemia results in a cascade of molecular, cellular, and tissue-level adaptations, often culminating in heart failure. Understanding the intricate biological mechanisms underlying this condition is crucial for its diagnosis and management.
Pathophysiology and Cardiac Remodeling
Section titled “Pathophysiology and Cardiac Remodeling”Ischemic cardiomyopathy is fundamentally a disease of cardiac remodeling, where the heart undergoes significant structural and functional alterations in response to chronic injury. This remodeling can manifest as cardiac hypertrophy, an increase in heart muscle mass, which initially serves as a compensatory mechanism to maintain cardiac output but can become maladaptive, leading to impaired function.[14]Accompanying these changes is cardiac fibrosis, characterized by the excessive accumulation of extracellular matrix proteins within the heart, which stiffens the tissue and further compromises its ability to pump blood.[30]The progression of these pathophysiological processes often results in a change in heart shape, with increased cardiac sphericity identified as an early marker of cardiomyopathy and related outcomes.[7]
Cellular and Metabolic Dysregulation
Section titled “Cellular and Metabolic Dysregulation”At the cellular level, cardiomyocytes in ischemic cardiomyopathy exhibit profound metabolic shifts and signaling pathway dysregulation. A hallmark change is the switch from efficient fatty acid (FA) metabolism to less energy-efficient glucose metabolism, which can be indicative of cardiomyopathy progression.[31] This metabolic reprogramming involves canonical pathways such as PPARA/RXRA activation, which governs FA beta-oxidation.[14] Various signaling pathways, including cardiac beta-adrenergic signaling and calcineurin/NFATcoupling, are critically involved, with the latter specifically participating in pathological rather than physiological cardiac hypertrophy.[14] Furthermore, the Orai1 protein has been identified to play a protective role in angiotensin-II-induced pathological cardiac remodeling, highlighting the importance of cellular ion channels and stress response pathways.[32]
Genetic Architecture and Molecular Components
Section titled “Genetic Architecture and Molecular Components”The development and progression of ischemic cardiomyopathy are significantly influenced by a complex genetic architecture involving numerous critical biomolecules and regulatory networks. Mutations in sarcomeric protein genes, which are essential for myocardial contraction, are frequently implicated; for instance, mutations in the cardiac myosin binding protein-C gene (MYBPC3) are known to cause familial hypertrophic cardiomyopathy, and truncations ofTitinlead to dilated cardiomyopathy.[33] Other sarcomeric genes, such as alpha-myosin heavy chain (MYH6) and myosin light-chain 4 (MYL4), have also been associated with dilated, hypertrophic, or atrial cardiomyopathy phenotypes.[34] Beyond sarcomeres, genes like MYRIP, TRAPPC11, and SLC27A6are implicated in left ventricular hypertrophy, while a mutation inPhospholambancan cause dilated cardiomyopathy and heart failure, underscoring the diverse genetic underpinnings.[14]The polygenic background can also modify the penetrance of monogenic variants, highlighting the interplay between multiple genetic factors in disease expression.[17]
Systemic Influences and Compensatory Responses
Section titled “Systemic Influences and Compensatory Responses”Ischemic cardiomyopathy is not solely an isolated cardiac pathology but is also influenced by and contributes to systemic consequences and compensatory responses throughout the body. Systemic factors such as systolic blood pressure and glycemic traits have a notable impact on left ventricular structure and function, demonstrating how broader physiological parameters can affect cardiac health.[4] Hormones like aldosterone, acting through epithelial cell signaling, are recognized as potentially hypertrophic.[35]The heart itself also initiates compensatory mechanisms; for example, brain natriuretic peptide (BNP) plays a role in regulating cardiac fibrosis.[30] Furthermore, the proper development and maturation of the heart, including atrial chamber morphogenesis, are regulated by key biomolecules like Angiopoietin-1 and Pdzrn3, whose decrease is required for heart maturation and protects against heart failure.[36]
Cardiac Remodeling and Neurohormonal Signaling
Section titled “Cardiac Remodeling and Neurohormonal Signaling”Ischemic cardiomyopathy involves complex signaling cascades that drive pathological cardiac remodeling, often initiated by neurohormonal activation. The beta-adrenergic signaling pathway is a key regulator, where G protein-coupled receptor kinases, such asGRK5 and GRK2, play critical roles in desensitizing beta-adrenergic receptors and influencing heart development. A specific GRK5polymorphism, known to inhibit beta-adrenergic receptor signaling, has been identified as protective in heart failure, highlighting the therapeutic potential of modulating this pathway.[19] Additionally, aldosterone signaling, traditionally associated with epithelial cells, is recognized for its hypertrophic potential in cardiomyocytes, directly contributing to adverse remodeling.[14] This involves receptor activation leading to intracellular signaling cascades that regulate gene expression and cellular responses to stress.
Beyond adrenergic and aldosterone pathways, other crucial signaling networks contribute to cardiac hypertrophy. The calcineurin/NFATcoupling pathway is specifically implicated in pathological, but not physiological, cardiac hypertrophy, suggesting its role in maladaptive remodeling.[37] Furthermore, the p42/44 MAPK cascade is hyperactivated in conditions like Caveolin-3deficiency, which can lead to progressive cardiomyopathy, whileCaveolin-3overexpression can attenuate hypertrophy and increase natriuretic peptide expression.[38] Endothelial IGF-1receptor signaling also contributes to the complex interplay of growth factors and receptors that govern cardiac cell fate and function, indicating broad systems-level integration of these signaling mechanisms in disease progression.
Metabolic Reprogramming and Energy Homeostasis
Section titled “Metabolic Reprogramming and Energy Homeostasis”A hallmark of cardiomyopathy, including ischemic forms, is a shift in myocardial energy metabolism from predominant fatty acid (FA) oxidation to increased glucose utilization. This metabolic reprogramming is indicative of cardiac dysfunction, as cardiomyocytes typically rely heavily on FA beta-oxidation for energy production.[14] Key regulatory mechanisms in this metabolic shift include the PPARA/RXRA activation pathway, which controls genes involved in fatty acid metabolism, and the AMP-activated protein kinase (AMPK) pathway. Mutations in the gamma.[39] subunit of AMPKare known to cause familial hypertrophic cardiomyopathy, emphasizing the central role of energy compromise in the pathogenesis of cardiac diseases.[40]Mitochondrial function is intrinsically linked to energy metabolism, and its dysregulation contributes to disease. Stress responses, such asNRF2-mediated pathways, are crucial for protecting mitochondrial integrity and function against oxidative damage, playing a compensatory role in stressed cardiomyocytes.[14] The efficiency of these metabolic pathways and their regulatory controls, including gene regulation and allosteric control of enzymes, determines the heart’s ability to cope with ischemic stress. For instance, the fatty acid transport protein SLC27A6 and FATP1 are involved in regulating lipid uptake and metabolism, with variants in SLC27A6potentially influencing left ventricular hypertrophy.[14]
Protein Quality Control and Cytoskeletal Dynamics
Section titled “Protein Quality Control and Cytoskeletal Dynamics”Maintaining protein homeostasis and structural integrity is vital for cardiac function, and dysregulation in these areas contributes significantly to ischemic cardiomyopathy. The ubiquitin-proteasome system (UPS) is a critical regulatory mechanism involved in protein degradation and quality control. Dysregulation and increased activity of the UPS have been observed in cardiovascular diseases, including atherosclerosis, where it is associated with enhanced inflammation and plaque destabilization.[41] Specific E3 ligases, such as Fbxo25, are known to target and degrade cardiac-specific transcription factors, highlighting a precise regulatory control over gene expression and cellular processes.[41]The structural components of cardiomyocytes, particularly sarcomeric proteins, are often affected in cardiomyopathy. Mutations in large proteins likeTitin, which cause dilated cardiomyopathy, and in cardiac myosin binding protein-C, which lead to familial hypertrophic cardiomyopathy, underscore the importance of myofibrillar stability.[2]Furthermore, conditions like filaminopathy involve myofibrillar instability, exacerbated by acute exercise.[2] Small heat shock proteins such as Hspb7 and Hspb12are also crucial, regulating early steps of cardiac morphogenesis and actin filament assembly, with their loci implicated in various etiologies of systolic heart failure.[19] BAG3mutations also contribute to dilated cardiomyopathy, further illustrating the role of protein quality control and cytoskeletal organization in cardiac health.[19]
Cellular Stress Responses and Ion Homeostasis
Section titled “Cellular Stress Responses and Ion Homeostasis”The heart’s response to various cellular stressors, including ischemia and subsequent reperfusion, involves intricate regulatory mechanisms to maintain cellular viability and function. NRF2-mediated stress responses are critical for cellular protection against oxidative stress, a common feature of ischemic injury, by upregulating antioxidant and detoxification genes.[14]Alongside this, the endoplasmic reticulum (ER) stress response plays a significant role in maintaining protein folding and processing. Dysregulation of ER stress responses can lead to cellular dysfunction and apoptosis, contributing to disease progression.[41]Ion homeostasis, particularly calcium regulation, is fundamental to cardiomyocyte contractility and is frequently disrupted in cardiomyopathy.Orai1, a calcium channel protein, is important for maintaining stored calcium, and its cardiomyocyte-specific deletion has been shown to protect against angiotensin-II-induced pathological cardiac remodeling.[2] While Orai1 can maintain stored calcium through a non-clustering mechanism, it can evoke clustering if the endoplasmic reticulum is perturbed, demonstrating pathway crosstalk between calcium signaling and ER stress.[41]These integrated cellular stress responses and ion regulatory mechanisms represent critical points of pathway dysregulation and potential therapeutic targets in ischemic cardiomyopathy.
Early Detection, Diagnostic Utility, and Monitoring
Section titled “Early Detection, Diagnostic Utility, and Monitoring”Early and accurate diagnosis of ischemic cardiomyopathy is critical for timely intervention and improved patient outcomes. Advanced cardiac imaging techniques, such as echocardiography and cardiac magnetic resonance imaging (CMR), play a pivotal role in assessing cardiac structure and function. These methods allow for the quantification of left ventricular (LV) mass, dimensions, wall thickness, and ejection fraction, which are fundamental in diagnosing and characterizing cardiomyopathy.[12]Echocardiography, including speckle-tracking echocardiography, can detect subtle changes in global longitudinal and circumferential strain, providing sensitive markers for ventricular function and aiding in the early detection of conditions like uremic cardiomyopathy, which can overlap with other forms of heart failure.[42]Furthermore, deep learning-enabled analysis of medical images has introduced novel metrics, such as the LV sphericity index, which can predict the risk of incident cardiomyopathy, atrial fibrillation, and heart failure in individuals with otherwise normal cardiac chamber size and systolic function, offering a potential early marker for cardiovascular risk.[7]Monitoring strategies for ischemic cardiomyopathy also leverage these imaging modalities to track disease progression and evaluate the efficacy of treatment. Regular assessment of LV systolic dysfunction, defined as a diminished ejection fraction, is crucial.[12]The use of cardiac MRI phenotypes, which have been shown to be highly heritable, allows for comprehensive evaluation of cardiac morphology and function, contributing to a more precise understanding of disease trajectory and potential therapeutic targets.[19] Recommendations from professional bodies like the American Society of Echocardiography guide the standardized quantification of cardiac chambers, ensuring consistency and comparability in clinical practice and research.[43]
Prognostic Assessment and Risk Stratification
Section titled “Prognostic Assessment and Risk Stratification”Identifying individuals at high risk for adverse outcomes in ischemic cardiomyopathy is paramount for personalized medicine and prevention strategies. Various clinical and imaging parameters hold significant prognostic value, predicting disease progression, treatment response, and long-term implications. Left ventricular hypertrophy (LVH), for instance, is a well-established risk factor for heart failure, stroke, and cardiovascular mortality, particularly in certain populations like Black adults.[44]Beyond LV function, the assessment of right ventricular (RV) systolic function and pulmonary artery pressure provides independent and additive prognostic value in patients with chronic heart failure, regardless of the underlying etiology.[19]Studies have shown that RV structure itself is associated with the risk of heart failure and cardiovascular death, highlighting the importance of a comprehensive biventricular assessment.[19]Advanced imaging markers, such as the LV sphericity index, also contribute to risk stratification. An increased sphericity index predicts incident cardiomyopathy and related outcomes independently of traditional clinical factors and other imaging features, even if its genetic underpinnings show a shared architecture with non-ischemic cardiomyopathy.[7] These insights facilitate a more nuanced approach to risk assessment, allowing clinicians to identify vulnerable patients who may benefit from more aggressive interventions or tailored management plans. Genetic studies are also beginning to inform personalized medicine by identifying genetic susceptibility loci associated with prognostically important LV imaging phenotypes, which are highly heritable, thereby improving the prediction of outcomes and guiding treatment selection.[19]
Genetic Contributions and Associated Conditions
Section titled “Genetic Contributions and Associated Conditions”Ischemic cardiomyopathy often coexists with, or is influenced by, a range of associated conditions and genetic predispositions, creating complex clinical phenotypes. Genetic factors play a significant role in shaping cardiac structure and function, with prognostically important left ventricular imaging phenotypes demonstrating substantial heritability.[19]Genome-wide association studies have identified numerous genetic loci associated with cardiac morphogenesis and heart failure development, offering insights into the molecular mechanisms underlying cardiomyopathy.[19] For instance, specific genes like MYRIP, TRAPPC11, and SLC27A6have been implicated in left ventricular hypertrophy in populations of African ancestry, suggesting a genetic component to population-specific disease prevalence and severity.[14]Beyond intrinsic genetic factors, ischemic cardiomyopathy frequently presents alongside other cardiovascular risk factors and comorbidities. Conditions like systemic hypertension and diabetes, through their effects on systolic blood pressure and glycemic traits, respectively, can significantly influence left ventricular structure and function, contributing to the development and progression of cardiomyopathy.[2]Furthermore, while distinct, other forms of cardiomyopathy, such as hypertrophic cardiomyopathy, myocardial noncompaction, and dilated cardiomyopathy (both idiopathic and non-ischemic), can share overlapping clinical presentations or genetic pathways, making differential diagnosis crucial.[14]Understanding these genetic and environmental determinants, as well as the interplay with associated conditions like uremic cardiomyopathy in end-stage renal disease, is essential for comprehensive patient care and the development of targeted therapeutic strategies.[42]
Frequently Asked Questions About Ischemic Cardiomyopathy
Section titled “Frequently Asked Questions About Ischemic Cardiomyopathy”These questions address the most important and specific aspects of ischemic cardiomyopathy based on current genetic research.
1. My family has a history of heart issues; am I at higher risk for this weak heart condition?
Section titled “1. My family has a history of heart issues; am I at higher risk for this weak heart condition?”Yes, absolutely. Your genetic makeup significantly influences your susceptibility to coronary artery disease (CAD), which is the primary cause of this weak heart condition, ischemic cardiomyopathy. If close family members have had heart problems, particularly CAD, it suggests you might have inherited some genetic factors that increase your own risk.
2. Can my healthy lifestyle overcome my family’s heart history?
Section titled “2. Can my healthy lifestyle overcome my family’s heart history?”While you can’t change your genes, a healthy lifestyle is incredibly powerful. Genetics influence yoursusceptibilityto conditions like CAD and how your heart responds to chronic stress. However, maintaining a healthy diet, exercising regularly, and managing other risk factors can significantly mitigate genetic predispositions and help prevent or delay the onset of heart conditions.
3. Could a DNA test tell me my risk for a weak heart before I feel sick?
Section titled “3. Could a DNA test tell me my risk for a weak heart before I feel sick?”Potentially, yes. Genetic insights are increasingly used for risk stratification. DNA tests, particularly those looking at specific genetic markers (SNPs) identified through large studies, can help identify individuals who are predisposed to developing ischemic cardiomyopathy, even before symptoms appear. This information can guide preventive strategies.
4. I’m always tired and short of breath; could my genes be making my heart weak?
Section titled “4. I’m always tired and short of breath; could my genes be making my heart weak?”These symptoms are classic signs of heart failure, which is what ischemic cardiomyopathy can cause. While chronic lack of blood flow is the direct cause of the heart weakening, your genetic makeup plays a significant role in how susceptible you are to developing coronary artery disease and how your heart muscle responds to that damage. So, yes, your genes could be influencing this process.
5. Why did my heart get weak from blocked arteries when my friend’s didn’t?
Section titled “5. Why did my heart get weak from blocked arteries when my friend’s didn’t?”This highlights the role of individual genetic differences. Even with similar levels of blocked arteries (coronary artery disease), some people’s hearts are more genetically predisposed to developing significant damage and remodeling, leading to a weak heart (ischemic cardiomyopathy). Your genes influence how your heart muscle tolerates reduced blood flow and its ability to adapt or recover.
6. I had a stroke; does that mean my heart is also at risk for this condition?
Section titled “6. I had a stroke; does that mean my heart is also at risk for this condition?”There’s a strong connection. Research shows a shared genetic susceptibility between ischemic stroke and coronary artery disease. Since coronary artery disease is the leading cause of ischemic cardiomyopathy, having experienced an ischemic stroke suggests you might have a broader genetic predisposition to ischemic conditions, including those affecting your heart.
7. Can knowing my genes help my doctor treat my weak heart better?
Section titled “7. Can knowing my genes help my doctor treat my weak heart better?”Absolutely. Understanding your genetic profile can be very valuable. Genetic insights are increasingly used to guide more personalized therapeutic strategies for ischemic cardiomyopathy. This precision medicine approach can help doctors tailor treatments to your specific genetic makeup, potentially leading to more effective interventions.
8. I have high blood pressure and sugar; does that make my genetic risk worse?
Section titled “8. I have high blood pressure and sugar; does that make my genetic risk worse?”Yes, these physiological traits can interact with your genetic risk. High systolic blood pressure and elevated glycemic traits significantly impact the structure and function of your left ventricle, the main pumping chamber of your heart. If you already have a genetic predisposition to heart issues, these factors can accelerate the damage and progression of ischemic cardiomyopathy.
9. If I have this heart condition, will my children definitely get it?
Section titled “9. If I have this heart condition, will my children definitely get it?”Not necessarily “definitely.” While your genetic makeup significantly influences your susceptibility to ischemic cardiomyopathy, it’s a complex condition. Your children will inherit some of your genetic predispositions, but whether they develop the condition also depends on other genetic factors they inherit, lifestyle, and environmental influences. It’s about increased risk, not certainty.
10. Does my genetic risk for a weak heart increase as I get older?
Section titled “10. Does my genetic risk for a weak heart increase as I get older?”The damageto your heart from chronic ischemia tends to accumulate over time, leading to a weaker heart. Your underlying genetic risk factors for coronary artery disease and how your heart responds to that damage are present throughout your life. While the genetic predisposition itself doesn’t “increase” with age, its effects become more pronounced as the chronic process unfolds, making the condition more likely to manifest or worsen in later years.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Pirruccello, J. P., et al. “Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy.”Nat Commun, vol. 11, no. 1, 2020, p. 2244.
[2] Khurshid S, Clinical and genetic associations of deep learning-derived cardiac magnetic resonance-based left ventricular mass. Nat Commun, PMID: 36944631
[3] Dichgans, M., et al. “Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants.”Stroke, vol. 45, no. 1, 2014, pp. 24-32.
[4] Hendriks, T. et al. “Effect of systolic blood pressure on left ventricular structure and function: a Mendelian randomization study.”Hypertension, vol. 74, 2019, pp. 826–832.
[5] Arnett DK. “Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study.”BMC Med Genet, 2009.
[6] Vasan RS, Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA, PMID: 19584346
[7] Vukadinovic M. “Deep learning-enabled analysis of medical images identifies cardiac sphericity as an early marker of cardiomyopathy and related outcomes.”Med, 2023.
[8] Thanaj M. “Genetic and environmental determinants of diastolic heart function.” Nat Cardiovasc Res, 2022.
[9] Vasan RS. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, 2007.
[10] Erdmann J, New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet, PMID: 19198612
[11] Agopian AJ, Genome-Wide Association Studies and Meta-Analyses for Congenital Heart Defects. Circ Cardiovasc Genet, PMID: 28468790
[12] Vasan RS. “Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data.” JAMA, 2009.
[13] Samani, N. J., et al. “Genomewide association analysis of coronary artery disease.”N Engl J Med., 2007.
[14] Irvin, M. R. et al. “Whole-Exome Sequencing and hiPSC Cardiomyocyte Models Identify MYRIP, TRAPPC11, and SLC27A6of Potential Importance to Left Ventricular Hypertrophy in an African Ancestry Population.”Front Genet, 2021.
[15] Bai, W. et al. “Automated cardiovascular magnetic resonance image analysis with fully convolutional networks.”J. Cardiovasc. Magn. Reson., vol. 20, no. 65, 2018.
[16] Onishi, T. et al. “Global longitudinal strain and global circumferential strain by speckle-tracking echocardiography and feature-tracking cardiac magnetic resonance imaging: comparison with left ventricular ejection fraction.” J Am Soc Echocardiogr, vol. 28, no. 5, 2015, pp. 587–596.
[17] Fahed, A. C. et al. “Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions.” Nat. Commun., vol. 11, no. 3635, 2020.
[18] Ntalla, I. et al. “Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction.” Nat. Commun., vol. 11, no. 2542, 2020.
[19] Aung, N. et al. “Genome-wide association analysis reveals insights into the genetic architecture of right ventricular structure and function.” Nat Genet, 2022.
[20] Do, A. N. et al. “Genome-wide meta-analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans.” Mol Genet Genomic Med, 2019.
[21] Seidman, C. E., et al. “Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy.”Nat. Genet., vol. 11, 1995, pp. 434–437.
[22] Daehmlow, S., et al. “Novel mutations in sarcomeric protein genes in dilated cardiomyopathy.”Biochem Biophys Res Commun, vol. 298, no. 1, 2002, pp. 116-120.
[23] Wild, P. S., et al. “Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function.” J Clin Invest, vol. 127, no. 5, 2017, pp. 1793-1804.
[24] Verweij, N., et al. “The genetic makeup of the electrocardiogram.” Cell Syst., vol. 11, 2020, pp. 229-238.e5.
[25] Mitchell, G. F., et al. “Common genetic variation in the 3′-BCL11B gene desert is associated with carotid-femoral pulse wave velocity and excess cardiovascular disease risk: the AortaGen Consortium.”Circ Cardiovasc Genet., vol. 5, no. 1, 2012, pp. 81–90.
[26] Nikpay, M., et al. “A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.”Nat Genet., vol. 47, no. 10, 2015, pp. 1121–1130.
[27] Ai, S. et al. “Effects of glycemic traits on left ventricular structure and function: a Mendelian randomization study.” Cardiovasc. Diabetol., vol. 21, no. 109, 2022.
[28] Noordam, R., et al. “Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration.” Nat Commun., 2019.
[29] Redheuil, A., et al. “Age-related changes in aortic arch geometry: relationship with proximal aortic function and left ventricular mass and remodel-ing.”J Am Coll Cardiol., vol. 58, no. 12, 2011, pp. 1262–1270.
[30] Tamura, N., et al. “Cardiac fibrosis in mice lacking brain natriuretic peptide.”Proc. Natl Acad. Sci. USA, vol. 97, 2000, pp. 4239–4244.
[31] Pascual, F. and Coleman, R. “The Role of Fatty Acid Metabolism in Cardiomyopathy.”Journal of Molecular and Cellular Cardiology, vol. 91, 2016, pp. 1-10.
[32] Segin, S., et al. “Cardiomyocyte-specific deletion of Orai1 reveals its protective role in angiotensin-II-induced pathological cardiac remodeling.” Cells, vol. 9, 2020, p. 1092.
[33] Watkins, H., et al. “Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy.”Nat. Genet., vol. 11, 1995, pp. 434–437.
[34] Carniel, E., et al. “Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy.”Circulation, vol. 112, 2005, pp. 54-59.
[35] Yamamuro, M., et al. “Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium.”Endocrinology, vol. 147, no. 3, 2006, pp. 1314-1321.
[36] Kim, K. H., Nakaoka, Y., Augustin, H. G., & Koh, G. Y. “Myocardial Angiopoietin-1 Controls Atrial Chamber Morphogenesis by Spatiotemporal Degradation of Cardiac Jelly.” Cell Rep., vol. 23, 2018, pp. 2455–2466.
[37] Wilkins, B. J., et al. “Calcineurin/NFATcoupling participates in pathological, but not physiological, cardiac hypertrophy.”Circ. Res., vol. 94, 2004, pp. 110–118.
[38] Shirani, J., et al. “Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade.”Journal of Molecular and Cellular Cardiology, vol. 34, no. 12, 2002, pp. 1625-1634.
[39] Ahmad, F., Seidman, J. G., & Seidman, C. E. “The genetic basis for cardiac remodeling.” Annu Rev Genomics Hum Genet, vol. 6, 2005, pp. 185-216.
[40] Kottgen, A., et al. “New loci associated with kidney function and chronic kidney disease.”Nature Genetics, vol. 42, no. 5, 2010, pp. 376-381.
[41] Kraus, W. E., et al. “Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis.”PLoS Genetics, vol. 11, no. 11, 2015, p. e1005510.
[42] Kramann, R. et al. “Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.”Journal of the American Society of Nephrology, 2014.
[43] Lang, R. M. et al. “Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.”Journal of the American Society of Echocardiography, 2015.
[44] Liao, Y. et al. “The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults.”American Journal of Medicine, 1999.